中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 7
Jul.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(7): 1541-1546

Association between transjugular intrahepatic portosystemic shunt and sarcopenia in patients with liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2023.07.005
  • 1.

    Department of Interventional Radiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 511407, China

  • 2.

    Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, China

More Information
  • Corresponding author: XIONG Bin, herrxiong@126.com (ORCID: 0000-0002-7795-7041)
  • Received Date: 2023-05-06
  • Accepted Date: 2023-06-06
  • Published Date: 2023-07-20
    Abstract
  • Sarcopenia is a common complication of liver cirrhosis and is significantly associated with poor prognosis. Transjugular intrahepatic portosystemic shunt (TIPS) is an important method for the treatment of portal hypertension and its complications. Based on current studies, this article analyzes the association between sarcopenia and the outcomes (hepatic encephalopathy and mortality) of patients with liver cirrhosis after TIPS and the value of improving the predictive ability of existing prognostic models for sarcopenia, as well as the improvement in sarcopenia after TIPS and its significance in the clinical management of patients with liver cirrhosis. A comprehensive analysis of existing reports show that baseline sarcopenia is associated with poor prognosis after TIPS, and it is thus recommended to evaluate nutritional status before TIPS based on radiological examination; TIPS can improve nutritional status and help to achieve reversal or improvement of sarcopenia to a certain extent, and it can also be translated into survival benefit. Therefore, for patients with sarcopenia and a relatively stable disease, TIPS can be performed as soon as possible after comprehensive evaluation.

     

    • FullText(HTML)
  • loading
    • References(42)
  • [1]
    MERLI M, RIGGIO O, DALLY L. Does malnutrition affect survival in cirrhosis? PINC (Policentrica Italiana Nutrizione Cirrosi)[J]. Hepatology, 1996, 23(5): 1041-1046. DOI: 10.1002/hep.510230516.
    [2]
    ALBERINO F, GATTA A, AMODIO P, et al. Nutrition and survival in patients with liver cirrhosis[J]. Nutrition, 2001, 17(6): 445-450. DOI: 10.1016/s0899-9007(01)00521-4.
    [3]
    LAI JC, TANDON P, BERNAL W, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021, 74(3): 1611-1644. DOI: 10.1002/hep.32049.
    [4]
    TANDON P, MONTANO-LOZA AJ, LAI JC, et al. Sarcopenia and frailty in decompensated cirrhosis[J]. J Hepatol, 2021, 75(Suppl 1): S147-S162. DOI: 10.1016/j.jhep.2021.01.025. PMID: 34039486.
    [5]
    BUNCHORNTAVAKUL C, REDDY KR. Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2020, 51(1): 64-77. DOI: 10.1111/apt.15571.
    [6]
    HAN HQ, ZHOU X, MITCH WE, et al. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential[J]. Int J Biochem Cell Biol, 2013, 45(10): 2333-2347. DOI: 10.1016/j.biocel.2013.05.019.
    [7]
    QIU J, THAPALIYA S, RUNKANA A, et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism[J]. Proc Natl Acad Sci U S A, 2013, 110(45): 18162-18167. DOI: 10.1073/pnas.1317049110.
    [8]
    DALLE S, ROSSMEISLOVA L, KOPPO K. The role of inflammation in age-related sarcopenia[J]. Front Physiol, 2017, 8: 1045. DOI: 10.3389/fphys.2017.01045.
    [9]
    LIU W, THOMAS SG, ASA SL, et al. Myostatin is a skeletal muscle target of growth hormone anabolic action[J]. J Clin Endocrinol Metab, 2003, 88(11): 5490-5496. DOI: 10.1210/jc.2003-030497.
    [10]
    LAKSHMAN KM, BHASIN S, CORCORAN C, et al. Measurement of myostatin concentrations in human serum: Circulating concentrations in young and older men and effects of testosterone administration[J]. Mol Cell Endocrinol, 2009, 302(1): 26-32. DOI: 10.1016/j.mce.2008.12.019.
    [11]
    GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases[J]. Hepatology, 2017, 65(1): 310-335. DOI: 10.1002/hep.28906.
    [12]
    de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Corrigendum to 'Baveno VⅡ - Renewing consensus in portal hypertension'[J Hepatol (2022) 959-974][J]. J Hepatol, 2022, 77(1): 271. DOI: 10.1016/j.jhep.2022.03.024.
    [13]
    European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease[J]. J Hepatol, 2019, 70(1): 172-193. DOI: 10.1016/j.jhep.2018.06.024.
    [14]
    CAREY EJ, LAI JC, WANG CW, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease[J]. Liver Transpl, 2017, 23(5): 625-633. DOI: 10.1002/lt.24750.
    [15]
    SU H, RUAN J, CHEN T, et al. CT-assessed sarcopenia is a predictive factor for both long-term and short-term outcomes in gastrointestinal oncology patients: a systematic review and meta-analysis[J]. Cancer Imaging, 2019, 19(1): 82. DOI: 10.1186/s40644-019-0270-0.
    [16]
    ZENG X, SHI ZW, YU JJ, et al. Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China[J]. J Cachexia Sarcopenia Muscle, 2021, 12(6): 1948-1958. DOI: 10.1002/jcsm.12797.
    [17]
    KONG M, GENG N, ZHOU Y, et al. Defining reference values for low skeletal muscle index at the L3 vertebra level based on computed tomography in healthy adults: A multicentre study[J]. Clin Nutr, 2022, 41(2): 396-404. DOI: 10.1016/j.clnu.2021.12.003.
    [18]
    BHANJI RA, MOCTEZUMA-VELAZQUEZ C, DUARTE-ROJO A, et al. Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis[J]. Hepatol Int, 2018, 12(4): 377-386. DOI: 10.1007/s12072-018-9875-9.
    [19]
    NARDELLI S, LATTANZI B, MERLI M, et al. Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis[J]. Hepatology, 2019, 70(5): 1704-1713. DOI: 10.1002/hep.30692.
    [20]
    NARDELLI S, LATTANZI B, TORRISI S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement[J]. Clin Gastroenterol Hepatol, 2017, 15(6): 934-936. DOI: 10.1016/j.cgh.2016.10.028.
    [21]
    YANG C, ZHU X, LIU J, et al. Development and validation of prognostic models to estimate the risk of overt hepatic encephalopathy after TIPS creation: A multicenter study[J]. Clin Transl Gastroenterol, 2022, 13(3): e00461. DOI: 10.14309/ctg.0000000000000461.
    [22]
    PRAKTIKNJO M, BOOK M, LUETKENS J, et al. Fat-free muscle mass in magnetic resonance imaging predicts acute-on-chronic liver failure and survival in decompensated cirrhosis[J]. Hepatology, 2018, 67(3): 1014-1026. DOI: 10.1002/hep.29602.
    [23]
    PRAKTIKNJO M, CLEES C, PIGLIACELLI A, et al. Sarcopenia is associated with development of acute-on-chronic liver failure in decompensated liver cirrhosis receiving transjugular intrahepatic portosystemic shunt[J]. Clin Transl Gastroenterol, 2019, 10(4): e00025. DOI: 10.14309/ctg.0000000000000025.
    [24]
    LI T, LIU J, ZHAO J, et al. Sarcopenia defined by psoas muscle thickness predicts mortality after transjugular intrahepatic portosystemic shunt[J]. Dig Dis Sci, 2023, 68(4): 1641-1652. DOI: 10.1007/s10620-022-07806-z.
    [25]
    MONTANO-LOZA AJ, DUARTE-ROJO A, MEZA-JUNCO J, et al. Inclusion of sarcopenia within MELD (MELD-Sarcopenia) and the prediction of mortality in patients with cirrhosis[J]. Clin Transl Gastroenterol, 2015, 6(7): e102. DOI: 10.1038/ctg.2015.31.
    [26]
    van VUGT J, ALFERINK L, BUETTNER S, et al. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort[J]. J Hepatol, 2018, 68(4): 707-714. DOI: 10.1016/j.jhep.2017.11.030.
    [27]
    BAI YW, LIU JC, YANG CT, et al. Inclusion of sarcopenia improves the prognostic value of MELD score in patients after transjugular intrahepatic portosystemic shunt[J]. Eur J Gastroenterol Hepatol, 2022, 34(9): 948-955. DOI: 10.1097/MEG.0000000000002391.
    [28]
    RONALD J, BOZDOGAN E, ZAKI IH, et al. Relative sarcopenia with excess adiposity predicts survival after transjugular intrahepatic portosystemic shunt creation[J]. AJR Am J Roentgenol, 2020, 214(1): 200-205. DOI: 10.2214/AJR.19.21655.
    [29]
    XIONG B, YANG C, ZHU X, et al. The added value of sarcopenia on existing risk scores to predict mortality after TIPS placement: A multicenter study[J]. Acad Radiol, 2023. DOI: 10.1016/j.acra.2023.03.011.[Online ahead of print]
    [30]
    BENMASSAOUD A, ROCCARINA D, ARICO F, et al. Sarcopenia does not worsen survival in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt for refractory ascites[J]. Am J Gastroenterol, 2020, 115(11): 1911-1914. DOI: 10.14309/ajg.0000000000000959.
    [31]
    XIONG B, YANG C, ZHOU C, et al. TIPS placement as the first-line therapy to prevent variceal rebleeding in patients with cirrhosis and sarcopenia[J]. Eur J Radiol, 2023, 158: 110630. DOI: 10.1016/j.ejrad.2022.110630.
    [32]
    PLAUTH M, SCHVTZ T, BUCKENDAHL DP, et al. Weight gain after transjugular intrahepatic portosystemic shunt is associated with improvement in body composition in malnourished patients with cirrhosis and hypermetabolism[J]. J Hepatol, 2004, 40(2): 228-233. DOI: 10.1016/j.jhep.2003.10.011.
    [33]
    MONTOMOLI J, HOLLAND-FISCHER P, BIANCHI G, et al. Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis[J]. World J Gastroenterol, 2010, 16(3): 348-353. DOI: 10.3748/wjg.v16.i3.348.
    [34]
    TSIEN C, SHAH SN, MCCULLOUGH AJ, et al. Reversal of sarcopenia predicts survival after a transjugular intrahepatic portosystemic stent[J]. Eur J Gastroenterol Hepatol, 2013, 25(1): 85-93. DOI: 10.1097/MEG.0b013e328359a759.
    [35]
    ARTRU F, MIQUET X, AZAHAF M, et al. Consequences of TIPSS placement on the body composition of patients with cirrhosis and severe portal hypertension: a large retrospective CT-based surveillance[J]. Aliment Pharmacol Ther, 2020, 52(9): 1516-1526. DOI: 10.1111/apt.16080.
    [36]
    WELLS CI, MCCALL JL, PLANK LD. Relationship between total body protein and cross-sectional skeletal muscle area in liver cirrhosis is influenced by overhydration[J]. Liver Transpl, 2019, 25(1): 45-55. DOI: 10.1002/lt.25314.
    [37]
    EBADI M, WANG CW, LAI JC, et al. Poor performance of psoas muscle index for identification of patients with higher waitlist mortality risk in cirrhosis[J]. J Cachexia Sarcopenia Muscle, 2018, 9(6): 1053-1062. DOI: 10.1002/jcsm.12349.
    [38]
    JAHANGIRI Y, PATHAK P, TOMOZAWA Y, et al. Muscle gain after transjugular intrahepatic portosystemic shunt creation: time course and prognostic implications for survival in cirrhosis[J]. J Vasc Interv Radiol, 2019, 30(6): 866-872. e4. DOI: 10.1016/j.jvir.2019.01.005.
    [39]
    GIOIA S, MERLI M, NARDELLI S, et al. The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS[J]. Liver Int, 2019, 39(5): 871-877. DOI: 10.1111/liv.14050.
    [40]
    LIU J, MA J, YANG C, et al. Sarcopenia in patients with cirrhosis after transjugular intrahepatic portosystemic shunt placement[J]. Radiology, 2022, 303(3): 711-719. DOI: 10.1148/radiol.211172.
    [41]
    LIU J, YANG C, YAO J, et al. Improvement of sarcopenia is beneficial for prognosis in cirrhotic patients after TIPS placement[J]. Dig Liver Dis, 2023. DOI: 10.1016/j.dld.2023.01.001.[Online ahead of print]
    [42]
    HUANG S, LIU J, CAI J, et al. Predictors of improvement of sarcopenia after transjugular intrahepatic portosystemic shunt creation in cirrhotic patients[J]. J Vasc Interv Radiol, 2023, 34(4): 639-644. DOI: 10.1016/j.jvir.2022.12.474.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (441) PDF downloads(100) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return